CLAIMS

1. Use of drospirenone or a pharmaceutical composition comprising drospirenone in the manufacture of a medicament for treating endometriosis, endometriosis associated pelvic pain (EAPP), endometriosis-associated symptoms, and/or dysmenorrhea in a female subject, wherein drospirenone is to be administered in a biphasic regimen to said subject, wherein a daily amount of drospirenone of 3.0 mg to 6.0 mg is to be administered from day 1 to day 24, and wherein a lower daily amount of drospirenone of 2.5 mg to 3.5 mg is to be administered from day 25 to 28, and wherein the subject is not to be administered with an estrogen.

2. Use of drospirenone or a pharmaceutical composition comprising drospirenone in the manufacture of a medicament for providing contraception to a female subject, wherein the drospirenone is to be administered in a biphasic regimen to said subject, wherein during the first phase a daily amount of drospirenone is to be administered and in the second phase a lower daily amount of drospirenone is to be administered, wherein the daily amount of drospirenone to be administered from day 1 to day 24 is from 3.0 mg to 6.0 mg, and wherein the lower daily amount of drospirenone to be administered from day 25 to 28 is from 2.5 mg to 3.5 mg, wherein the subject is not to be administered with an estrogen.

3. The use according to claims 1 or 2, wherein the endometriosis-associated symptoms comprise symptoms selected from the group consisting of premenstrual pain, dyspareunia, and chronic fatigue.

4. The use according to any one of claims 1 to 3, wherein said daily amount of drospirenone is to be administered once daily from day 1 to day 24 and subsequently a lower daily amount of drospirenone is to be administered once daily on days 25 to 28.

5. The use according to any one of claims 1 to 4, wherein the daily amount of drospirenone to be administered from day 1 to day 24 is from 3.0 mg to 5.0 mg, more preferred from 3.5 mg to 4.5 mg, even more preferred from 3.8 mg to 4.2 mg, most preferred about 4.0 mg of drospirenone.

6. The use according to any one of claims 1 to 5, wherein the lower daily amount of drospirenone to be administered from day 25 to 28 is from 2.6 mg to about 3.2 mg, more preferred about 3.0 mg, most preferred about 2.8 mg of drospirenone.

7. The use according to any one of claims 1 to 6, wherein the daily amount of drospirenone to be administered from day 1 to day 24 is 4.0 mg and the lower daily amount of drospirenone to be administered from day 25 to 28 is 2.8 mg.

8. The use according to any one of claims 1 to 7, wherein drospirenone to be administered via an administration route selected from oral, transdermal or transmucosal administration, preferably wherein the administration route is oral.

9. The use according to any one of claims 1 to 8, wherein the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients, preferably wherein the said pharmaceutically acceptable excipients are at least one binder and at least one filler, and wherein:

(i) the amount of drospirenone accounts for 1 % to 10% by weight,

(ii) the amount of the at least one binder accounts for 50% to 65% by weight and

(iii) the amount of the at least one filler accounts for 25% to 35% by weight,

the percentages by weight being related to the total weight of the said pharmaceutical composition.

10. The use according to claim 9, wherein the pharmaceutical composition further comprising at least one glidant and at least one lubricant wherein:

(i) the amount of the at least one glidant accounts for 0.2% to 6% by weight and

(ii) the amount of the at least one lubricant accounts for 0.2% to 0.6% by weight

the percentages by weight being related to the total weight of the said pharmaceutical composition.

11. The use according to any one of claims 9 or 10, wherein:

(i) the at least one binder is microcrystalline cellulose;

(ii) the at least one filler is anhydrous lactose;

(iii) the at least one glidant is silicon dioxide; and

(iv) the at least one lubricant is magnesium stearate.

12. A kit for use in the treatment of endometriosis, endometriosis associated pelvic pain (EAPP), endometriosis-associated symptoms, dysmenorrhea in a female subject, and/or for providing contraception, the kit comprising one or more packaging units, wherein each packaging unit comprises at least 28 active daily dosage units, wherein:

a) at least 24 daily dosage units comprise a first amount of drospirenone, wherein each of these daily dosage units comprise the same amount of drospirenone, and

the amount is higher than the amount of drospirenone in the daily dosage units of a second amount of drospirenone, wherein the subject is not to be administered with an estrogen; and

b) at least 4 daily dosage units comprising the second amount of drospirenone, wherein each of these daily dosage units comprise the same amount of drospirenone, and the amount of drospirenone is lower than in the daily dosage units comprising the first amount of drospirenone, wherein the subject is not to be administered with an estrogen.

13. The kit according to claim 12, wherein, drospirenone is the only contraceptive active ingredient in the at least 28 active daily dosage units.

14. The kit according to claims 12 or 13, wherein the first amount of drospirenone is from 3.0 mg to 6.0 mg, and wherein the second amount of drospirenone is from 2.5 mg to 3.5 mg, and drospirenone is the only contraceptive active ingredient in the at least 28 active daily dosage units.

15. The kit according to any one of claims 12-14, wherein the first amount of drospirenone is from 3.0 mg to 5.0 mg, more preferred from 3.0 mg to 4.5 mg, even more preferred from 3.8 mg to 4.2 mg, most preferred about 4.0 mg of drospirenone.

16. The kit according to any one of claims 12-15, wherein the second amount of drospirenone is from 2.6 mg to 3.2 mg, more preferred about 3.0 mg, most preferred about 2.8 mg of drospirenone.